Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Heart and Blood Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Thrombosis

Pulmonary Embolism

Embolism

Thromboembolism

Venous Thromboembolism

Venous Thrombosis

Carcinoma

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Embolism and Thrombosis

Vascular Diseases

Ovarian Cancer

Ovarian Epithelial Cancer

Patients with ovarian, tubar or primary peritoneal cancer

Patients with suspected ovarian cancer where the final pathologic diagnosis is benign

Ole Thorlacius-Ussing, MD, DMSc

Objectives of the study are: To estimate the incidence of venous thromboembolism (VTE) in a cohort of women with suspected ovarian cancer and evaluate changes in the coagulation system in case of benign or malignant disease. The impact of changes in the coagulation system on disease prognosis will be evaluated.

Venous thromboembolism (VTE) is a common complication after surgery. Deep-vein thrombosis (DVT) and pulmonary embolism (PE) constitute VTE. PE is often a consequence of DVT and it is a feared complication and the most common preventable cause of hospital death. VTE can be asymptomatic and can be detected by a compression ultrasound scan (CUS) of the legs and a Computer Tomography (CT) of the lungs. It is wellknown that cancer patients are at higher risk of developing VTE, the risk is approximately seven times higher than in the background population. A Danish study showed a significantly higher risk of death when VTE was diagnosed at the same time as the cancer diagnosis with a 12 % one year survival compared to 36 % in cancer patients without a history of VTE.

Approximately 600 women in Denmark are diagnosed with ovarian cancer every year and it is the forth most common cause of cancer death among Danish women. Earlier studies have found that up to 31 % of ovarian cancer women develop VTE as a consequence of the disease and/or the treatment. Very few studies have examined the incidence of VTE before treatment.

Methods: A Pulmonary CT-angiography is included in the routinely performed Fluorodeoxyglucose Positron Emission Tomography - Computer Tomography (FDG PET-CT) to reveal pulmonary embolism at time of first referral. Compressive ultrasound scan including Doppler flow of the lower extremities is performed four times from first referral and during a one-year follow up period to detect clinical or subclinical deep vein thrombosis (DVT) before and after initiation of treatment.

Blood and tissue samples are taken, prepared and stored at -80 degrees in the Danish Cancer-Biobank for later analyzes of coagulation markers.

Immune histochemical techniques will be use to demonstrate tissue factor (TF) in tumor tissue.

The objectives of the study are:

1. In a prospective study at Aalborg University Hospital to estimate the incidence of clinical and subclinical venous thromboembolism (VTE) in patients with suspected ovarian cancer before and after initiation of treatment. The impact of VTE on survival will be evaluated.
2. In the same prospective cohort the correlation between markers of coagulation and fibrinolysis and subclinical VTE, tumour burden and overall survival will be evaluated.
3. Evaluate the correlation between immunohistochemical demonstrated tissue factor (TF) in tumour tissue and circulating TF in peripheral blood and the relation to VTE and tumour burden.

Tumor tissue and also healthy tissue for comparison are taken at surgery. Blood samples.

Venous Thromboembolic Complications in Ovarian Cancer

Venous Thromboembolic Complications in Patients With Ovarian Cancer Compared to Patients With Benign Ovarian Tumours

Compressive ultrasound scan of lower extremities and pulmonary CT-angiography

Evaluation of classic and novel coagulation markers and their relation to prognosis

Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery

Professor

Infections

Lung Neoplasms

Pneumonia

Computed Tomography

Thomas Frauenfelder, PD MD

Marga Rominger, Prof MD

Evaluation of ultra low dose protocols and Iomeron 400 contrast in PCD-CT

Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT

mSv per exam will be recorded. This value will be put in correlation to weight (Kg), height (cm) and BMI.

Recorded values compared in 2 populations-different contrast agents by using qualitative\&quantitative methods Qualitative:diagnostic certainty, assessability of lung structure/lesions,diagnostic reliability,

Quantitative:Assessment of tissue composition,diagnostic performance measurements Attenuation/sealing measurement (HU), signal-to-noise ratio (SNR), contrast-to-noise ratio ,size dimensions of lung structure/lesion in three dimensions in millimeters Tissue composition assessment diagnostic performance measurements (sensitivity, specificity, accuracy) diagnostic confidence: 1-4

Theses measurements will be put in correlation to the scan dose (mSv) per patient, forming two groups with matched BMI (kg/m\^2)

University of Zurich

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Venous Thromboembolic Complications in Ovarian Cancer	NCT02480790	Venous Thromboe... Ovarian Neoplas... Ovarian Cancer Deep Vein Throm... Lung Embolism		18 Years - 100 Years	Aalborg University Hospital
Venous Thromboembolic Complications in Ovarian Cancer	NCT02480790	Venous Thromboe... Ovarian Neoplas... Ovarian Cancer Deep Vein Throm... Lung Embolism		18 Years - 100 Years	Aalborg University Hospital
Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT	NCT06360627	Radiation Expos... Lung Embolism Lung Cancer Pneumonia	Computed Tomogr...	18 Years -	University of Zurich
Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT	NCT06360627	Radiation Expos... Lung Embolism Lung Cancer Pneumonia	Computed Tomogr...	18 Years -	University of Zurich

Spots Global Cancer Trial Database for lung embolism